Full-Time

Fellow – AI Architecture

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Compensation Overview

$243.1k - $437k/yr

+ Annual discretionary bonus + Equity award

No H1B Sponsorship

Cambridge, MA, USA

Hybrid

Hybrid work model; majority on-site with 70% in-office culture.

US Citizenship Required

Category
Software Engineering (1)
Required Skills
LLM
Microsoft Azure
ServiceNow
Workday HRIS
Computer Networking
OpenAI
SAP Products
Role-based Access Control
AWS
OAuth
Google Cloud Platform
Requirements
  • Bachelor’s degree in computer science, Engineering or related field
  • Minimum of 10 years’ experience of hands-on architecting AI/ML solutions in large, global commercial organizations
  • Deep expertise in multi-cloud environments (GCP, AWS, Azure), including security, networking, and cost optimization
  • Proven track record with large language models and agentic frameworks, including protocols A2A and MCP
  • Demonstrated success integrating third-party AI/agentic platforms into complex IT landscapes
  • Hands-on experience designing and operating multi-agent orchestration frameworks
  • Strong background in identity and access management frameworks (RBAC, ABAC, OAuth, Zero Trust)
Responsibilities
  • Define and advance Moderna’s AI strategy, ensuring alignment with business goals, security standards, and process requirements
  • Architect and manage scalable solutions across Google Cloud Platform (GCP), Amazon Web Services (AWS), and Microsoft Azure
  • Lead design and deployment of large language model (LLM) services and agentic capabilities, leveraging protocols such as A2A and MCP
  • Architect and enforce agentic identity and access controls using role-based, attribute-based, and Zero Trust models
  • Implement security protections against AI-specific threats—adversarial attacks, data poisoning, model theft, prompt injection—across the data, model, and application stack
  • Evaluate, integrate, and customize third-party agentic solutions from across the wider technology landscape (Microsoft, Amazon, OpenAI, Workday, SAP, ServiceNow, etc.) to accelerate AI-driven workflows
  • Drive rigorous build-vs-buy analyses for agentic implementations, recommending when to leverage partner ecosystem solutions
  • Design and implement AI solutions requiring multi-agent orchestration, ensuring agents communicate, collaborate, and escalate appropriately
  • Partner with AI Digital business owners to help prioritize, prototype, iterate, and productionize secure AI solutions
  • Assist in aligning or creating business and technical processes—data flows, governance, change management—to unlock and scale AI opportunities
  • Present architectural blueprints, risk assessments, and ROI analyses to senior leadership, tailoring communications for technical and non-technical audiences
  • Mentor and coach cross-functional teams, fostering a culture of security-minded innovation, continuous learning, and humility
  • Additional duties as may be assigned from time to time
Desired Qualifications
  • Advanced degree in Computer Science, Engineering or related field
  • Experience designing and implementing AI security defenses against adversarial and data integrity threats
  • Proven ability to collaborate with Data Architecture teams and Systems Data Owners on governance, metadata, and integration
  • Demonstrated ability to influence diverse stakeholders using solution value rather than title or hierarchy
  • Creative thinker with a talent for envisioning transformative AI use cases and converting big ideas into enterprise-grade implementations
  • Exceptional analytical skills with experience leading build-vs-buy evaluations for enterprise software
  • Excellent communication skills; adept at distilling complex technical, security, and process considerations into clear, concise narratives for executives
  • Experience in health sciences or life sciences environments is a plus

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna Direct can streamline healthcare ordering and bypass traditional distributors.
  • CEPI funding de-risks Bundibugyo ebolavirus development and parallel manufacturing.
  • Regulator-aligned COVID strain updates support annual respiratory vaccine revenues.

What critics are saying

  • Bundibugyo vaccine remains preclinical, with no human efficacy data yet.
  • COVID strain selection missteps can cede 2026-2027 share to Pfizer and Sanofi.
  • Lingering lipid nanoparticle litigation threatens platform economics and future licensing costs.

What makes Moderna unique

  • mRNA platform targets protein production directly inside human cells.
  • Founded in 2010, Moderna built a leading mRNA technology platform.
  • Commercial products include Spikevax and Mresvia, alongside broad pipeline candidates.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Moderna who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
The New York Ledger
May 30th, 2026
Moderna, Inc. (MRNA) presents at Bernstein 42nd Annual Strategic Decisions Conference transcript.

Moderna, Inc. (MRNA) presents at Bernstein 42nd Annual Strategic Decisions Conference transcript. Moderna, Inc. (MRNA) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDT Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Institutional Services LLC, Research Division Presentation Courtney Breen Bernstein Institutional Services LLC, Research Division Welcome, everyone. Thank you so much for joining York Ledger for this conversation about Moderna. My name is Courtney Breen. I am the U.S. pharma analyst here at Bernstein. And it is my privilege to have Stephane Bancel here with me, the CEO and Chairman of Moderna. He's been in this role for a decent amount of time as well and has seen Moderna through the ages and through the different eras of the company. So I'm really excited to kind of have an opportunity to dive into kind of Moderna today, where Moderna has come from and where Moderna might be going in the future. I also know that AI is a super important topic for all investors these days. So York Ledger'll be hoping to touch on kind of the impact and potential of AI and drug discovery and kind of in operating some of these businesses. But I do also want to remind you that if there are other topics that I'm not planning on covering that you'd love to have covered in this conversation, please do send them through the Pigeonhole app. You'll find a QR code to be able to send them through. I'll receive them up here and can integrate them into the conversation. So York Ledger want to make this as relevant and as impactful for everyone that's here. Question-and-Answer Session Courtney Breen Bernstein Institutional Services LLC, Research Division But without further ado, Stephane, again, thank you so much for joining York Ledger here today. As I mentioned, you've been leading Moderna for a while, I think, since 2011. It

Logicity
Apr 11th, 2026
The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough.

The 'V' Word: Why Moderna is Ditching 'Vaccine' for its Cancer Breakthrough. Moderna is rebranding its cancer treatment, a promising mRNA-based therapy, to distance itself from vaccine skepticism. This move has sparked debate among medical professionals and raises questions about transparency in clinical trials. Can a simple name change impact the future of cancer treatment? Key takeaways. * Moderna's cancer treatment uses mRNA technology to target specific cancer cells * The company has rebranded its treatment as 'individualized neoantigen therapy' to avoid vaccine skepticism * Medical professionals are divided on the impact of this name change on patient trust and transparency * The Science Behind mRNA Therapy * Moderna and Merck Team Up to Take on Cancer * The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' * What the Experts Think: Reactions to Moderna's Rebranding * The Future of Cancer Treatment: Implications and Next Steps * Conclusion: The Road Ahead for Moderna's Cancer Breakthrough The Science Behind mRNA Therapy. Imagine a treatment that can specifically target and kill cancer cells, while leaving healthy cells intact. This is the promise of mRNA therapy, which uses genetic code to program the immune system to attack cancer cells. * mRNA therapy works by sequencing a patient's cancer cells to identify unique molecules, called neoantigens * These neoantigens are then used to create a personalized treatment that instructs the immune system to attack cancer cells Moderna and Merck Team Up to Take on Cancer. Moderna has partnered with Merck to develop its mRNA-based cancer treatment, with impressive results in clinical trials. But as the company moves forward, it's facing a new challenge: vaccine skepticism. * Moderna and Merck have shown that their treatment can halve the chance of cancer recurrence in patients with the deadliest form of skin cancer * The partnership has led to a rebranding of the treatment as 'individualized neoantigen therapy', a move that's sparked debate among medical professionals The 'V' Word Dilemma: Why Moderna is Ditching 'Vaccine' In an effort to distance itself from vaccine controversy, Moderna has stopped using the term 'vaccine' to describe its cancer treatment. But is this move a smart PR strategy, or a recipe for confusion? * Moderna's CEO has said that the rebranding is intended to 'better describe the goal of the program' * However, some medical professionals argue that the change could raise questions about transparency and patient trust What the Experts Think: Reactions to Moderna's Rebranding. Logicity Pvt Ltd spoke to medical professionals and experts in the field to get their take on Moderna's decision to rebrand its cancer treatment. Here's what they had to say. * Some experts, like Ryan Sullivan, a physician at Massachusetts General Hospital, are concerned that the name change could impact patient trust and transparency * Others, like Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre, believe that the move is a necessary step to avoid vaccine skepticism The Future of Cancer Treatment: Implications and Next Steps. As Moderna moves forward with its rebranded cancer treatment, the company faces a complex landscape of regulatory hurdles, patient trust, and public perception. What does the future hold for this promising therapy? * The success of Moderna's treatment could pave the way for a new generation of cancer therapies * However, the company must navigate a complex regulatory environment and address concerns about transparency and patient trust Conclusion: The Road Ahead for Moderna's Cancer Breakthrough. As the debate around Moderna's rebranding continues, one thing is clear: the future of cancer treatment is complex and multifaceted. What's next for this promising therapy, and how will it impact the lives of patients around the world? * Moderna's treatment has the potential to revolutionize cancer care, but it must navigate a complex landscape of regulatory hurdles and public perception * The company's decision to rebrand its treatment as 'individualized neoantigen therapy' is just the beginning of a larger conversation about transparency, trust, and the future of medicine "Vaccines are maybe a dirty word nowadays, but we still believe in the science and harnessing our immune system to not only fight infections, but hopefully to also fight... cancers" - Kyle Holen, head of Moderna's cancer program "There is some concern that there will be patients who decline to treat their cancer because it is a vaccine" - Ryan Sullivan, physician at Massachusetts General Hospital Final thoughts. As Logicity Pvt Ltd look to the future of cancer treatment, it's clear that Moderna's rebranding is just the beginning of a larger conversation about transparency, trust, and the role of language in shaping its perceptions of medicine. Will the company's move pay off, or will it spark more controversy? Only time will tell, but one thing is certain: the future of cancer care is complex, multifaceted, and full of promise. Sources & credits. Huma Shazia Senior AI & Tech Writer

MedWatch
Apr 9th, 2026
IO Biotech founder after bankruptcy: "our work is far from wasted"

IO Biotech founder after bankruptcy: "our work is far from wasted" The founder and CEO denies that funds have been wasted. IO Biotech's technology lives on with competitors such as moderna, which, according to Mai-Britt Zocca, has copied the company's core program. 9 April 2026at 15:21 Since its founding in 2015 and up until its recent bankruptcy, investors have poured well over DKK 2bn (USD 313m) into the biotech company IO Biotech, but even though the company has now collapsed, that money has not been wasted, according to founder and CEO Mai-Britt Zocca. Try MedWatch for 14 days - and get access to all content. * Continues as a recurring subscription and is billed annually. Can be terminated after 5 months of subscription with 1 month's notice at the end of a month. Minimum price is up to €539.58 excl. VAT corresponding to 7 months of subscription. Right of withdrawal under the Consumer Contracts Act. Read more here. ** Continues as a recurring subscription for 3 months at a time. Minimum price €286.00 excl. VAT. Can be terminated with 1 month's notice at the end of a 3-month period. Right of withdrawal under the Consumer Contracts Act. Read more here.

StockStory
Apr 3rd, 2026
2 S&P 500 stocks with Exciting potential and 1 We ignore.

2 S&P 500 stocks with Exciting potential and 1 We ignore. Radek strnad /. April 2, 2026 The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Some large-cap stocks are past their peak, and StockStory is here to help you separate the winners from the laggards. Keeping that in mind, here are two S&P 500 stocks leading the market forward and one best left off your watchlist. One stock to sell: Moderna (MRNA). Market Cap: $19.51 billion Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases. Why Do We Avoid MRNA? * Customers postponed purchases of its products and services this cycle as its revenue declined by 46.7% annually over the last two years * Earnings per share fell by 30.2% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable * Free cash flow margin dropped by 178.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up Two stocks to buy: AMD (AMD). Market Cap: $354.6 billion Founded in 1969 by a group of former Fairchild semiconductor executives led by Jerry Sanders, Advanced Micro Devices (NASDAQ:AMD) is one of the leading designers of computer processors and graphics chips used in PCs and data centers. Why Are We Bullish on AMD? * Annual revenue growth of 28.8% over the past five years was outstanding, reflecting market share gains this cycle * Exciting sales outlook for the upcoming 12 months calls for 34.8% growth, an acceleration from its two-year trend * Earnings per share have comfortably outperformed the peer group average over the last five years, increasing by 26.4% annually AMD's stock price of $217.20 implies a valuation ratio of 31.7x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. Texas Pacific Land (TPL). Market Cap: $30.63 billion One of America's largest private landowners with roughly 868,000 acres in the Permian Basin, Texas Pacific Land (NYSE:TPL) owns land in West Texas and earns revenue from oil and gas royalties, water services, and land leases. Why Is TPL a Top Pick? * Annual revenue growth of 26.2% over the past ten years was outstanding, reflecting market share gains this cycle * Highly-profitable operating model results in strong unit economics and a best-in-class gross margin of 95% * TPL is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $444.10 per share, Texas Pacific Land trades at 32.8x forward EV-to-EBITDA. Is now the time to initiate a position? See for yourself in our in-depth research report, it's free. Stocks We like even more. ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies. Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Yahoo Finance
Apr 1st, 2026
Moderna settles patent dispute and shifts to cancer therapy as analysts see 71% upside

Moderna has raised investor attention following a patent dispute settlement and its pivot toward individualised cancer therapies. Trading at $50.80, the stock has posted a 72% 90-day return and 87% one-year total shareholder return, though it remains down 67% over three years. Despite reporting a $2.8 billion loss, the leading valuation thesis argues Moderna is 71% undervalued, with a fair value estimate of $175. This view emphasises the company's reinvestment of pandemic windfall profits into its mRNA platform and pipeline whilst maintaining low debt levels. The company currently trades below book value, with its valuation dependent on whether its late-stage pipeline, recurring vaccine revenue and future oncology products can generate sustained cash flows beyond its COVID-19 success.